α -Ketoglutarate accumulation is not dependent on isocitrate dehydrogenase activity during tellurite detoxification in Escherichia coli.

Biomed Res Int

Departamento de Biología, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago 9170000, Chile.

Published: August 2014

Tellurite is toxic to most microorganisms because of its ability to generate oxidative stress. However, the way in which tellurite interferes with cellular processes is not fully understood to date. In this line, it was previously shown that tellurite-exposed cells displayed reduced activity of the α-ketoglutarate dehydrogenase complex (α-KGDH), which resulted in α-ketoglutarate (α-KG) accumulation. In this work, we assessed if α-KG accumulation in tellurite-exposed E. coli could also result from increased isocitrate dehydrogenase (ICDH) and glutamate dehydrogenase (GDH) activities, both enzymes involved in α-KG synthesis. Unexpectedly both activities were found to decrease in the presence of the toxicant, an observation that seems to result from the decreased transcription of icdA and gdhA genes (encoding ICDH and GDH, resp.). Accordingly, isocitrate levels were found to increase in tellurite-exposed E. coli. In the presence of the toxicant, cells lacking icdA or gdhA exhibited decreased reactive oxygen species (ROS) levels and higher tellurite sensitivity as compared to the wild type strain. Finally, a novel branch activity of ICDH as tellurite reductase is presented.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859025PMC
http://dx.doi.org/10.1155/2013/784190DOI Listing

Publication Analysis

Top Keywords

isocitrate dehydrogenase
8
α-kg accumulation
8
tellurite-exposed coli
8
presence toxicant
8
icda gdha
8
tellurite
5
-ketoglutarate accumulation
4
accumulation dependent
4
dependent isocitrate
4
dehydrogenase
4

Similar Publications

Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years.

View Article and Find Full Text PDF

Background/objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy.

Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers.

View Article and Find Full Text PDF

Purpose: Glioblastomas contacting the subventricular zone (SVZ) are associated with poor prognosis and the impact of ventricular entry (VE) during resection remains controversial. Since glioblastomas with SVZ involvement often require VE, both SVZ involvement and VE are confounding factors. This study aimed to evaluate the effect of VE during glioblastoma resection by comparing patients with and without SVZ involvement.

View Article and Find Full Text PDF

Malignant gliomas are heterogeneous tumors, mostly incurable, arising in the central nervous system (CNS) driven by genetic, epigenetic, and metabolic aberrations. Mutations in isocitrate dehydrogenase (IDH1/2) enzymes are predominantly found in low-grade gliomas and secondary high-grade gliomas, with IDH1 mutations being more prevalent. Mutant-IDH1/2 confers a gain-of-function activity that favors the conversion of a-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG), resulting in an aberrant hypermethylation phenotype.

View Article and Find Full Text PDF

Deep learning MRI models for the differential diagnosis of tumefactive demyelination versus -wildtype glioblastoma.

AJNR Am J Neuroradiol

January 2025

From the Department of Radiology (GMC, MM, YN, BJE), Department of Quantitative Health Sciences (PAD, MLK, JEEP), Department of Neurology (CBM, JAS, MWR, FSG, HKP, DHL, WOT), Department of Neurosurgery (TCB), Department of Laboratory Medicine and Pathology (RBJ), and Center for Multiple Sclerosis and Autoimmune Neurology (WOT), Mayo Clinic, Rochester, MN, USA; Dell Medical School (MFE), University of Texas, Austin, TX, USA.

Background And Purpose: Diagnosis of tumefactive demyelination can be challenging. The diagnosis of indeterminate brain lesions on MRI often requires tissue confirmation via brain biopsy. Noninvasive methods for accurate diagnosis of tumor and non-tumor etiologies allows for tailored therapy, optimal tumor control, and a reduced risk of iatrogenic morbidity and mortality.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!